fluorodeoxyglucose f18 has been researched along with rivastigmine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alva, G; Anand, R; Carreon, D; Fallon, JH; Fleming, K; Hartman, R; Keator, D; Messina, J; Potkin, SG; Wu, JC | 1 |
| Almkvist, O; Forsberg, A; Långström, B; Nilsson, A; Nordberg, A; Stefanova, E; Wall, A | 1 |
2 trial(s) available for fluorodeoxyglucose f18 and rivastigmine
| Article | Year |
|---|---|
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Chemistry; Carbamates; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Radiopharmaceuticals; Rivastigmine; Tomography, Emission-Computed | 2001 |
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition; Energy Metabolism; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose; Humans; Longitudinal Studies; Male; Neuropsychological Tests; Phenylcarbamates; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Nicotinic; Rivastigmine; Severity of Illness Index | 2006 |